Lakeway, TX -- (SBWIRE) -- 02/20/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-
Lululemon Athletica inc. (NASDAQ:LULU) shares jumped 2.80% and closed at $69.75 in the last trading session. The company, on Jan. 14, announced that for the fourth quarter of 2012, it expects net revenue to be at the high end of its original guidance range of $475 million to $480 million. The Company also now expects diluted earnings per share will be $0.74 for the quarter. The previous guidance for the fourth quarter was a range of 0.71 to $0.73. EPS guidance continues to assume 145.9 million diluted weighted average shares outstanding and a 29.4% tax rate. Analysts on an average are expecting the Company to report EPS of $0.74 for the fourth quarter of 2012.
How Should Investors Trade LULU After The Recent Movement? Find Out Here
Huntsman Corporation (NYSE:HUN) shares gained 2.80% to $17.64. The company, last week, posted fourth quarter loss of $40 million, or 17 cents a share, compared with a profit of $105 million, or 44 cents a share, a year earlier. Adjusted earnings for the quarter fell to 24 cents from 28 cents. Revenue edged down 0.5% to $2.62 billion. Analysts most recently forecast a profit of 23 cents a share on revenue of $2.49 billion.
Is HUN Strong Buy After The Recent Strong Gains? Get Free Trend Analysis Here
ConocoPhillips (NYSE:COP) shares climbed 2.77% and closed at $58.60. The company recently obtained clearance to resume full operations at an oilfield off the China’s northeastern coast after being suspended in 2011 due to oil spill. The country’s State Oceanic Administration announced Saturday that the Penglai 19-3 oil field located in northern Bohai Bay could now fully operate after changes were made, ending a 17-month shutdown.
Is COP a Buying Opportunity After The Recent Plunge? Don’t Miss Out Our Latest Report Here
Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares increased 2.77% and closed at $2.97. The company reported new negative results from a clinical trial of an experimental treatment for Fabry disease, a rare genetic disorder. Amicus said the drug, which is called migalastat, did not meet secondary goals in the study. In December, Amicus and its partner GlaxoSmithKline said the drug had not met the main goal in the trial.
How Should Investors Trade FOLD After The Latest Earnings Report? Find Out Here
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)